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Wilkins.Background: There is considerable variation in
hypertension prevalence and awareness, and their
correlates, across different geographic locations and ethnic
groups. We performed this cross-sectional analysis on data
from the Golestan Cohort Study (GCS).
Methods: Enrollment in this study occurred in 2004–
2008, and included 50045 healthy individuals from
Golestan Province in northeastern Iran. Hypertension was
defined as a SBP at least 140mmHg, a DBP at least
90mmHg, a prior diagnosis of hypertension, or the use of
antihypertensive drugs. Potential correlates of hypertension
and its awareness were analyzed by logistic regression
adjusted for sex, age, BMI, place of residence, literacy,
ethnicity, physical activity, smoking, black and green tea
consumption and wealth score.
Results: Of the total cohort participants, 21 350 (42.7%)
were hypertensive. Age-standardized prevalence of
hypertension, using the 2001 WHO standard world
population, was 41.8% (95% confidence interval: 38.3–
45.2%). Hypertension was directly associated with female
sex, increased BMI, Turkmen ethnicity, and lack of physical
activity, and inversely associated with drinking black tea
and wealth score. Among hypertensive patients, 46.2%
were aware of their disease, 17.6% were receiving
antihypertensive medication, and 32.1% of the treated
patients had controlled hypertension. Hypertension
awareness was greater among women, the elderly,
overweight and obese patients, and those with a higher
wealth score.
Conclusion: Hypertension is highly prevalent in rural Iran,
many of the affected individuals are unaware of their
disease, and the rate of control by antihypertensive
medications is low. Increasing hypertension awareness and
access to health services, especially among less privileged
residents are recommended.
Keywords: awareness, hypertension, obesity, smoking,
socioeconomic status
Abbreviations: CVA, cerebrovascular accidents; CVD,
cardiovascular disease; FFQ, food frequency questionnaire;
GCS, Golestan Cohort Study; NHANES, National Health
and Nutrition Examination Survey; NO, nitric oxide; SES,
socioeconomic statusCopyright © Lippincott Williams & Wilkins. Unaut
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he age-standardized prevalence of hypertension
ranges between 5.5% in a rural part in India and
40% in Spain [1]. Although the average global preva-
lence of hypertension has declined slightly during the past
two decades, there is an increasing trend in the middle and
low income countries [2–4], and about two-thirds of
patients with hypertension are now living in developing
countries [1]. Iran is a Middle Eastern, middle-income
country with diverse ethnicities and lifestyles across the
country. A systematic review of published studies from Iran
has estimated the prevalence of hypertension to be 22.1%
[2]. There is considerable variation in the hypertension
prevalence across different geographic locations, and eth-
nic groups [5]. A high proportion of hypertensive patients
are unaware of their condition; for example, in the Iranian
national household survey, only 34% of hypertensive
patients knew they were hypertensive [6]. Studies from
big cities like Tehran (50%) and Isfahan (43.8%) reported
higher rates of awareness [7,8].
Polypill, a single-capsule combination of medications
that lower blood pressure and serum cholesterol levels, is
being evaluated for use in the primary and secondary
prevention of cardiovascular disease (CVD) in those whose
only risk factor is old age [9,10]. A number of trials havehorized reproduction of this article is prohibited.
DOI:10.1097/HJH.0b013e3283613053
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Hypertension prevalence and awareness in Iransupported the effectiveness of polypill, both in those who
have risk factors for CVD and those who do not [11–16], but
there is still a need for larger trials [17]. A pilot double-blind
randomized controlled trial using polypill to control the
main risk factors of CVD in Golestan Province, Iran has
shown the safety, feasibility and effectiveness of this inter-
vention [18], and a pragmatic main phase trial, POLYIRAN,
conducted in the context of the Golestan Cohort Study
(GCS), has already started [19,20]. GCS is a cohort of more
than 50 000 adults fromGolestan Province (2010 population
approximately 1700 000), a mainly rural area in northeast-
ern Iran [21]. This cohort was primarily designed to study
esophageal cancer in this high-risk area [22,23]. The first
5-year follow-up data of this cohort revealed that 50% of
deaths were due to CVD and cerebrovascular accidents,
and up to 33% of patients in a preliminary study were found
to be hypertensive [24].
In the present study, we performed a cross-sectional
analysis of the baseline data from GCS to report the crude
and age-adjusted rates and correlates of hypertension and
factors associated with awareness of hypertension in this
population. These findings can be helpful in interpreting
the results of the POLYIRAN trial, and provide a better
perspective of hypertension, as an important CVD risk
factor, in this mainly rural area.
METHODS
Study population
We performed this cross-sectional analysis on the data from
the Golestan Cohort Study, which has been described
before [22]. This study enrolled patients during 2004–
2008, and included 50 045 healthy adults from 40 to 75
years old. About 20% of the participants were urban res-
idents, randomly selected according to household numbers
from five clustered areas of Gonbad, the second largest city
in Golestan, and 80% were rural residents selected from all
326 villages in the planned area of the study. The study
protocol was approved by the ethical committees of the
Digestive Disease Research Center, the National Cancer
Institute, and the International Agency for Research on
Cancer.
Each interview was done by a trained general prac-
titioner and a nutritionist. Two structured questionnaires,
a lifestyle questionnaire and a food frequency question-
naire (FFQ), were given to each subject to collect infor-
mation about age, sex, ethnicity, place of living, past
medical history, drug use, household properties, education,
and use of tobacco. After the interview, a short physical
examination, including blood pressure measurement, was
done, and blood, urine, hair and nail samples were
collected.
The definitions of the covariate variables used in this
analysis have been extensively explained before [25] and
are briefly described here. Literacy was defined as more
than 1 year of attendance in school. Physical activity was
defined based on occupational activity; those having jobs
involving heavy and intense physical activity were coded as
active, and all others were coded as sedentary. Weight and
height were measured wearing light clothes but no shoes,
to calculate BMI. BMI was categorized according to theCopyright © Lippincott Williams & Wilkins. Unauth
Journal of HypertensionWHO classification: underweight (BMI< 18.5 kg/m2),
normal (BMI 18.5–24.9 kg/m2), overweight (BMI 25–
29.9 kg/m2), and obese (BMI over 30 kg/m2) [26]. Our study
included eight different ethnicities, which we combined
into the two major groups, Turkmen and non-Turkmen.
Quartiles of black tea drinking were calculated among
normotensive individuals and were used as the basis for
classification of all individuals. As there were not many
people who drank green tea regularly, individuals were
classified only as drinkers or nondrinkers of green tea. The
smoking history was recorded and divided into five
categories: those who never smoked, those who smoked
more than the median pack-years of the normotensive
population (heavy smokers), those who smoked less than
the median pack-years of the normotensive population
(light smokers), those who had quit smoking (ex-smokers),
and individuals who used other tobacco products (e.g.
nass, hookah, or pipe).
Definition of hypertension
The blood pressure was measured twice in each arm in the
sitting position. There was a 2-min rest between each two
measurements. A person’s blood pressure was calculated as
the average of the two measurements in each arm. Accord-
ing to the JNC7 criteria [27], hypertension was defined as a
SBP at least 140mmHg, a DBP at least 90mmHg, a prior
clinical diagnosis of hypertension, or the use of antihyper-
tensive drugs. Those hypertensives who self-reported hav-
ing hypertension were considered aware of their disease,
and those who took antihypertensive drugs were con-
sidered under treatment. Patients taking antihypertensive
medication who had both SBP less than 140mmHg and
DBP less than 90mmHg were defined as having controlled
hypertension.
Statistical analysis
Age-standardization was calculated using the 2001 WHO
standard world population [28], with the exact method for
calculating confidence intervals. In order to classify the
socioeconomic status, a wealth score was calculated as
explained elsewhere [25], using multiple correspondence
analysis. In calculating this composite wealth score, house
ownership, house size, number of people living in the
house and ownership of appliances such as car, TV,
refrigerator, and so on were used.
Logistic regression was used, with hypertension as the
outcome in every body, and awareness of hypertension
only among hypertensive individuals. For crude associ-
ations, each variable (i.e., sex, age, BMI, place of residence,
literacy, ethnicity, physical activity, smoking, black and
green tea consumption and wealth score) was entered in
the model alone. Two adjusted models were evaluated: in
the first, we adjusted for age and sex only, and in the
second, all of the variables were entered in the model.
Most of these variables were selected based on their pre-
viously shown effect on cardiovascular disease risk, in
general, and on hypertension and its awareness, in particu-
lar. Unlike coffee intake, there are only a few articles
published about the association between tea intake and
hypertension. As most people in this population drink tea
frequently (median intake of 1035ml per day), and suchorized reproduction of this article is prohibited.
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Malekzadeh et al.data were available in detail, we used this opportunity to
study both black and green tea consumption in the models.
Two-tailed P< 0.05 were considered significant.
RESULT
Of the total cohort participants, 21 350 (42.7%) were hyper-
tensive: 31.6% of those below the age of 50, 49.3% between
50 and 60 years old, and 61.8% above 60 (Table 1). The age-
standardized prevalence of hypertension using the 2001
WHOstandardworldpopulationwas 41.8% [95%confidence
interval (CI): 38.3–45.2%]. Hypertensionwasmore prevalent
inwomen (46.4 vs. 37.6%,P< 0.0001). The age-standardized
prevalence in women was 44.1% (95% CI: 40.6–47.6%), and
in men it was 33.1% (95% CI: 30.6–35.5%). In unadjusted
models, hypertension was associated with increasing BMI,
Turkmen ethnicity, lack of physical activity at work, and
drinking green tea. There were fewer hypertensives amongCopyright © Lippincott Williams & Wilkins. Unaut
TABLE 1. Factors associated with hypertension in the Golestan Coho
Hypertensive,
number (%)
Normotensive,
number (%)
Total 21 350 (42.7) 28 695 (57.3)
Sex
Male 7985 (37.6) 13 249 (62.4)
Female 13 365 (46.4) 15 446 (53.6)
Age
Below 50 7991 (31.6) 17 323 (68.4)
50–60 years 7559 (49.3) 7784 (50.7)
Above 60 5800 (61.8) 3588 (38.2)
BMI
Underweight 597 (24.8) 1813 (75.2)
Normal 5939 (33.1) 11 990 (66.9)
Overweight 7678 (45.2) 9294 (54.8)
Obese 7130 (56.0) 5594 (44.0)
Place of residence
Rural 17 173 (42.9) 22 839 (57.1)
Urban 4177 (41.6) 5856 (58.4)
Literacy
Illiterate 16 382 (46.7) 18 736 (53.4)
Literate 4968 (33.3) 9959 (66.7)
Ethnicity
Turkmen 16247 (43.6) 21 006 (56.4)
Non-Turkmen 5103 (39.9) 7689 (60.1)
Physical activity
No 19599 (44.3) 24 629 (55.7)
Yes 1751 (30.1) 4064 (69.9)
Smoking
Never 17 578 (44.8) 21 629 (55.2)
Light smoker 632 (28.0) 1621 (72.0)
Heavy smoker 949 (29.9) 2228 (70.1)
Ex-smoker 1277 (39.7) 1941 (60.3)
Others 914 (41.7) 1276 (58.3)
Black tea
Q1 (<690ml) 6919 (46.3) 8017 (53.7)
Q2 (691–1035ml) 5103 (42.8) 6823 (57.2)
Q3 (1036–1500ml) 4874 (41.5) 6884 (58.6)
Q4 (>1500ml) 4454 (39.0) 6971 (61.0)
Green tea
Nondrinker 17 623 (42.4) 23 915 (57.6)
Drinker 3727 (43.8) 4780 (56.2)
Wealth score
1 unit increase – –
CI, confidence interval; NA, not applicable; OR, odds ratio.
aModel 1: adjusted for age and sex.
bModel 2: including all variables in the table.
1366 www.jhypertension.comunderweight individuals, people living in towns, literate
people, smokers, and those drinkingmore black tea. Hyper-
tension was also inversely associated with the composite
wealth score. Adjusting for age and sex attenuated the effects
of smoking and drinking green tea. In the fully adjusted
model, the associations between hypertension and age, BMI
and place of residence were more pronounced than the
crudemodel, and the inverse association among ex-smokers
was no longer significant (Table 1). Table 2 shows the factors
associated with hypertension separately for rural and urban
residents. Place of residence showed significant interactions
with sex, literacy, physical activity, and wealth score
(P< 0.001). Sex and physical activity showed significant
associations with hypertension only in rural villages,
whereas markers of socioeconomic status (SES) (literacy
and wealth score) had stronger associations in urban areas.
Nine thousand, eight hundred and seventy-one (46.2%)
of the hypertensive patients were aware of their disease,horized reproduction of this article is prohibited.
rt Study
Crude OR
(95% CI)
Model 1a OR
(95% CI)
Model 2b OR
(95% CI)
1 NA 1
1.44 (1.38–1.49) 1.11 (1.06–1.17)
1 NA 1
2.11 (2.02–2.19) 2.20 (2.11–2.30)
3.51 (3.34–3.69) 4.29 (4.05–4.53)
0.66 (0.60–0.73) 0.59 (0.53–0.65) 0.59 (0.53–0.65)
1 1 1
1.67 (1.60–1.74) 1.84 (1.75–1.92) 1.87 (1.79–1.96)
2.57 (2.46–2.70) 2.95 (2.81–3.11) 3.06 (2.90–3.22)
1 1 1
0.95 (0.91–0.99) 0.90 (0.86–0.94) 0.85 (0.81–0.90)
1 1 1
0.57 (0.55–0.59) 0.88 (0.84–0.92) 0.84 (0.80–0.89)
1 1 1
0.86 (0.82–0.89) 0.80 (0.77–0.84) 0.91 (0.87–0.95)
1 1 1
0.54 (0.51–0.57) 0.74 (0.69–0.78) 0.82 (0.77–0.88)
1 1 1
0.48 (0.44–0.53) 0.62 (0.56–0.69) 0.75 (0.68–0.83)
0.52 (0.48–0.57) 0.61 (0.56–0.66) 0.79 (0.73–0.87)
0.81 (0.75–0.87) 0.81 (0.75–0.88) 0.92 (0.85–1.00)
0.88 (0.81–0.96) 0.73 (0.67–0.80) 0.87 (0.79–0.96)
1 1 1
0.87 (0.83–0.91) 0.89 (0.85–0.94) 0.92 (0.88–0.97)
0.82 (0.78–0.86) 0.85 (0.81–0.90) 0.90 (0.85–0.95)
0.74 (0.70–0.78) 0.79 (0.75–0.83) 0.86 (0.81–0.91)
1 1 1
1.06 (1.01–1.11) 1.01 (0.96–1.06) 1.00 (0.98–1.02)
0.84 (0.77–0.92) 1.10 (1.00–1.21) 0.75 (0.67–0.83)
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TABLE 2. Factors associated with hypertension in rural and urban areas in the Golestan Cohort Study
Rural areas OR (95% CI) Urban areas OR (95% CI)
Sex
Male 1 1
Female 1.17 (1.10–1.24) 0.94 (0.83–1.05)
Age
Below 50 1 1
50–60 years 2.14 (2.04–2.25) 2.49 (2.26–2.75)
Above 60 4.13 (3.87–4.40) 4.87 (4.33–5.49)
BMI
Underweight 0.59 (0.53–0.66) 0.57 (0.42–0.78)
Normal 1 1
Overweight 1.89 (1.79–1.99) 1.73 (1.55–1.93)
Obese 3.05 (2.88–3.24) 2.93 (2.61–3.30)
Literacy
Illiterate 1 1
Literate 0.88 (0.83–0.94) 0.77 (0.69–0.85)
Ethnicity
Turkmen 1 1
Non-Turkmen 0.90 (0.86–0.95) 1.00 (0.92–1.01)
Physical activity
No 1 1
Yes 0.79 (0.73–0.85) 0.97 (0.80–1.17)
Smoking
Never 1 1
Light smoker 0.75 (0.67–0.84) 0.73 (0.58–0.93)
Heavy smoker 0.80 (0.72–0.88) 0.76 (0.63–0.91)
Ex-smoker 0.90 (0.82–0.99) 0.96 (0.80–1.15)
Others 0.88 (0.79–0.98) 1.00 (0.76–1.32)
Black tea
Q1 (<690ml) 1 1
Q2 (691–1035ml) 0.92 (0.86–0.97) 0.95 (0.84–1.06)
Q3 (1036–1500ml) 0.91 (0.86–0.96) 0.86 (0.77–0.96)
Q4 (>1500ml) 0.86 (0.81–0.92) 0.87 (0.77–0.98)
Green tea
Nondrinker 1 1
drinker 0.99 (0.97–1.01) 1.04 (1.00–1.09)
Wealth score
1 unit increase 0.86 (0.76–0.97) 0.54 (0.44–0.67)
Hypertension prevalence and awareness in Iran3756 (38.1% of the aware patients, and 17.6% of everyone
with high blood pressure) were receiving antihypertensive
medication, and 1205 (32.1% of the treated patients, and
5.6% of all hypertensives) had controlled hypertension.
Awareness of being hypertensive was significantly higher
in women. It was also more common in older patients,
overweight and obese patients, urban residents, illiterates,
those with less physical activity and never-smokers
(Table 3). Hypertension awareness was also directly associ-
ated with the composite wealth score. After adjusting for
confounders, the associations with urban residence and
current smoking were no longer significant, and hyper-
tension awareness was significantly higher in ex-smokers.
The composite wealth score also had a higher odds ratio in
the adjusted models (Table 3).
DISCUSSION
In this study, the age-standardized prevalence of hyperten-
sion was 41.8%, and less than half of the hypertensives
knew that they had this condition. Hypertension and its
awareness were more prevalent among women, obese and
less active people, and illiterates. Current (but not past)
smoking was associated with a lower chance of having highCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionblood pressure, but hypertensive ex-smokers were more
aware of their condition. The prevalence of hypertension
showed an inverse relationship with the amount of black
tea used. Higher wealth score was associated with lower
chance of hypertension, and more awareness.
The overall 41.8% prevalence of hypertension in this
study was higher than in many published reports from Iran
and other countries, probably due to the higher age of our
cohort population; the age-specific prevalences of hyper-
tension by decades in our study (31.6, 49.3 and 61.8% in the
40–49, 50–59 and 60–69 year old age groups, respectively)
were more similar to other reports. For example, Hagh-
doost et al. [2] estimated the national prevalence of hyper-
tension in Iran to be 22.1% among adults and 49.5% among
individuals older than 55 year old. Likewise, Esteghamati
et al. [6] reported the overall prevalence of hypertension to
be 25.2% in adults and 53.6% in the 55–64 year age group in
an Iranian national household survey of risk factors for
noncommunicable diseases. A worldwide study of hyper-
tension reported that 26.1, 37.2, 46.6 and 51.7% of adults
were hypertensive in the 40–49, 50–59, 60–69, and at least
70 year old age groups, respectively, in Middle Eastern
countries, lower rates than we found in Golestan Province,
and it reported hypertension rates of 32.4, 44.8, 60.3, andorized reproduction of this article is prohibited.
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TABLE 3. Factors associated with hypertension awareness among hypertensive individuals in the Golestan Cohort Study
Aware,
number (%)
Unaware,
number (%)
Crude OR
(95% CI)
Model 1a OR
(95% CI)
Model 2b OR
(95% CI)
Total 9871 (46.2) 11 479 (53.8)
Sex
Male 2549 (31.9) 5436 (68.1) 1 NA 1
Female 7322 (54.8) 6043 (45.2) 2.58 (2.44–2.74) 2.53 (2.34–2.74)
Age
Below 50 3099 (38.8) 4891 (61.2) 1 NA 1
50–60 years 3707 (49.0) 3854 (51.0) 1.52 (1.42–1.62) 1.62 (1.52–1.74)
Above 60 3065 (52.9) 2734 (47.1) 1.77 (1.65–1.89) 2.28 (2.11–2.47)
BMI
Underweight 225 (37.7) 372 (62.3) 0.99 (0.83–1.18) 0.88 (0.74–1.06) 0.88 (0.73–1.05)
Normal 2249 (37.9) 3690 (62.1) 1 1 1
Overweight 3516 (45.8) 4162 (54.2) 1.39 (1.29–1.49) 1.41 (1.31–1.52) 1.40 (1.30–1.50)
Obese 3881 (54.4) 3255 (45.6) 1.96 (1.82–2.10) 1.86 (1.72–2.00) 1.82 (1.68–1.96)
Place of residence
Rural 7710 (45.6) 9203 (54.4) 1 1 1
Urban 2161 (48.7) 2276 (51.3) 1.13 (1.06–1.21) 1.06 (0.99–1.14) 0.93 (0.86–1.00)
Literacy
Illiterate 8154 (49.8) 8228 (50.2) 1 1 1
Literate 1717 (34.6) 3251 (65.4) 0.53 (0.50–0.57) 0.97 (0.90–1.05) 0.84 (0.77–0.92)
Ethnicity
Turkmen 7449 (45.8) 8798 (54.2) 1 1 1
Non-Turkmen 2422 (47.5) 2681 (52.5) 1.07 (1.00–1.14) 1.01 (0.95–1.08) 1.08 (1.00–1.15)
Physical activity
No 9396 (47.9) 10 203 (52.1) 1 1 1
Yes 475 (27.1) 1276 (72.9) 0.40 (0.36–0.45) 0.67 (0.60–0.75) 0.70 (0.62–0.78)
Smoking
Never 8501 (48.4) 9077 (51.6) 1 1 1
Light smoker 209 (33.1) 423 (66.9) 0.53 (0.45–0.62) 1.00 (0.84–1.20) 1.11 (0.93–1.33)
Heavy smoker 276 (29.1) 673 (70.9) 0.44 (0.38–0.51) 0.88 (0.75–1.02) 1.01 (0.86–1.18)
Ex-smoker 500 (39.2) 777 (60.8) 0.69 (0.61–0.77) 1.28 (1.12–1.45) 1.34 (1.18–1.53)
Others 385 (42.1) 529 (57.9) 0.78 (0.68–0.89) 1.04 (0.90–1.20) 1.16 (1.00–1.35)
Wealth score
1 unit increase – – 1.36 (1.18–1.55) 1.77 (1.53–2.04) 1.55 (1.32–1.82)
CI, confidence interval; NA, not applicable; OR, odds ratio.
aModel 1: adjusted for age and sex.
bModel 2: including all variables in the table.
Malekzadeh et al.71.2% for these age groups in developed countries, figures
closer to our own [1]. The National Health And Nutrition
Examination Survey (NHANES) in the United States also had
similar results among American adults between 1999 and
2004 [29].
Reports from NHANES show no significant relation
between sex and hypertension in the United States. In Iran,
most studies show a higher prevalence of cardiovascular
risk factors, including hypertension [2] and the metabolic
syndrome [30], in women. A countrywide study showed a
slightly but not significantly higher prevalence of hyper-
tension among younger men, whereas the prevalence of
hypertension was significantly higher in older (45–64 year
old) women [5]. Although higher BMI and lack of physical
activity have been proposed as causes for this sex differ-
ence [30], in this study this difference was still significant
after adjusting for these other variables.
We observed a reduced prevalence of hypertension in
people reporting higher physical activity. Moderate regular
physical activity can reduce SBP and DBP about 10mmHg
in 75% of hypertensive patients [31]. Moreover, it has been
shown that physical fitness (as a consequence of regular
physical activity) has protective effects on hypertension
[32]. The underlying mechanisms by which physical activity
acts are probably weight loss, increased metabolic rate andCopyright © Lippincott Williams & Wilkins. Unaut
1368 www.jhypertension.comfat metabolism. Reduction in insulin resistance, plasma
norepinephrine, plasma renin and vascular resistance can
be other explaining mechanisms [33,34]. Physical activity
can be used as a therapeutic choice for the treatment of
hypertension and for prevention of its complications [35],
and it improves cardiac autonomic modulation and reduces
risk of coronary heart diseases [36].
Tea consists of different types of polyphenols (mostly
flavonoid) that stimulate the release of nitric oxide (NO) – a
strong vasodilator – from vascular endothelium and
thereby can reduce blood pressure [37,38]. Animal studies
consistently show that black tea consumption decreases
hypertension, but the results of human studies are less
consistent: some studies show that regular tea drinkers
have lower blood pressures than nondrinkers [38–40],
but others have failed to show a protective effect of short
periods of tea consumption [41]. We also found a lower
prevalence of hypertension in regular black tea users, and
an inverse dose–response relationship between the
amount of tea consumed and the risk of hypertension.
Green tea drinkers, however, were not different from non-
drinkers in our study. Although some studies on rats have
showed a protective effect for green tea on hypertension
[42,43], and green tea has more polyphenols and hence
should have more antioxidant activity than black tea, therehorized reproduction of this article is prohibited.
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Hypertension prevalence and awareness in Iranis as yet no evidence that green tea lowers blood pressure in
humans [38].
Talukder et al. observed that smoking leads to increased
blood pressure in mice, and suggested that this effect was
mediated by endothelial injury, increased reactive oxygen
species and decreased NO release [44]. Other possible
mechanisms are increased sympathetic activity induced
by nicotine, increased blood viscosity due to production
of more fibrinogen and augmented numbers of white blood
cells, and changes in serum lipid levels caused by smoking
[45–48]. Increased inflammatory mediators, such as C-reac-
tive protein, in a smoker’s bloodmay also be another reason
explaining this effect [49,50]. Some studies had shown that
smoking increases arterial stiffness [51,52],which secondarily
can raise bloodpressure. Aprospective cohort study in Japan
showed an independent and significant effect of smoking on
hypertension [53]. Halperin et al. [54] also found both past
and current smoking as risk factors for hypertension. The
finding of an inverse association between hypertension and
smoking in the present study is probably due to reverse
causation, due to the fact that people with hypertension are
more likely tobeadvisedby their doctors to giveup smoking.
Our cross-sectional analysis is not able to prove this, but two
pieces of evidence support it: we found that the inverse
association disappeared in ex-smokers after adjusting for
confounders and that ex-smokers were more aware of their
hypertension compared to never-smokers (i.e. people who
knew they were hypertensive were more likely to give up
smoking). This pattern was also found in a study from
Canada [55].
Higher SES and more education have been consistently
reported to reduce the risk of hypertension [29,56]. Studies
from Iran have also shown that people educated in second
school or higher were less likely to be hypertensive [5,57].
Similarly, we found hypertension to be inversely associated
with the composite wealth score and literacy. Possible
mechanisms for these associations proposed by other
investigators include lower birth weight, which has been
shown to impact blood pressure, lower awareness of hy-
pertension, resulting in less medical management and
poorer control, bad job conditions and job strains among
people with lower SES [58]. There are conflicting reports
about the effects of residential area on the prevalence of
hypertension; whereas most investigations have shown no
difference between rural and urban areas [2,5,57], one
national study in Iran reported higher rates in urban res-
idents [59], and a WHO report has also shown that hyper-
tension is more prevalent in urban areas in developing
countries of Africa [60]. In contrast, we observed a lower
prevalence of hypertension in urban areas of Golestan
Province, although it is important to note that this province
is mainly rural and even the towns are best described as
extended villages. We observed an interaction between the
place of residence and socioeconomic indicators, with a
stronger association between these indicators and hyper-
tension in urban areas. This may be due to more socio-
economic diversity in these urban areas, andmore potential
for a change in lifestyle as a result of this.
The rate of hypertension awareness was 46.2% in our
study, which is much less than similar awareness in the
United States [29]. A nationwide surveyof noncommunicableCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensiondiseases in Iran reported that 34% of people with high blood
pressure knew about it [6], and another large study in the
metropolitan area of Tehran found the awareness to be
49.6% [7]. Among our hypertensive patients, 17.6% were
treated and 32.1% of those treated had controlled hyperten-
sion. Similar to awareness, control rates in this population
were higher than the national average [6], and lower than
control rates in the United States [29]. We saw a higher
proportion of awareness in women, the elderly and people
with other medical conditions such as obesity, results similar
to previous studies [7,8,29,61,62]. Higher levels of awareness
in older and more obese people may be due to the closer
attention of thehealth system to these groups, and theirmore
frequent contact with healthcare professionals [63–66]. We
observedpoorer knowledgeofhypertension in lowerwealth
scores. Higher SES is probably related to better and easier
contact with health workers and more availability of infor-
mation technologies (e.g., TV, computer, etc.), which pre-
dictably lead to higher awareness. Van Rossum et al. [67]
showed lower awareness among less-educated men and
those men who lived without a partner. Living in rural areas
was significantly associated with the knowledge of hyper-
tension after adjusting for confounders. Existence of an
efficient health network in villages, including the presence
of local assistant health personnel (Behvarz) who are
engaged in vaccination, family health and other primary
healthcare functions and have good communication and
rapport with villagers, may be one reason for this higher
awareness. The cornerstone of primary healthcare (PHC) in
Iran is the Health House, which is staffed with one or two
Behvarzes. Golestan Province has 607 Health Houses and
1281 active Behvarzes. Each rural Health House is respon-
sible for 1000–1500 individuals on average [68,69]. In urban
areas, these Health Houses are replaced by Urban Health
Centers, which are responsible for providing PHC for about
15 000 people. One review evaluating the weaknesses of the
health system in Iran found that the flaws in thekey functions
of PHCoccurredmore frequently in urban than in rural areas
[70].
The existence of a relatively good primary healthcare
network on the one hand and the observed high prevalence,
low awareness, and low treatment and control rates on the
other hand suggest that some pragmatic measures may be
able to control hypertension and its complications in Gole-
stan Province. The use of polypill, a multidrug regimen for
the prevention of hypertension and CVD in low-income and
middle-income countries, is one potential strategy that has
already shown promise in previous studies [13,71]. More-
over, a recent meta-analysis and mortality estimation in Iran
found that using polypill in Iran could have prevented 28500
deathsdue to ischemicheart disease and12700deaths due to
stroke in 2006 [72,73]. Therefore, using polypill for primary
and secondary prevention of hypertension and CVD in the
general population seems to be a reasonable strategy to try in
this region. The results of the ongoing POLYIRAN clinical
trial will provide additional, stronger data to evaluate the
wisdom of such a strategy [20].
Strengths of this study included the large sample size and
the extensive collection of information on potentially
associated demographic and lifestyle factors. A major
limitation was the cross-sectional design of the analysis,orized reproduction of this article is prohibited.
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Malekzadeh et al.which made it difficult to rule out reverse causation,
particularly for smoking and tea consumption. Another
limitation was the fact that we measured blood pressure
at only one session rather than two office visits, which may
have led to some overestimation of the prevalence.
In conclusion, hypertension is a highly prevalent con-
dition in adults in this rural area of Iran. Many of the affected
individuals are unaware of their disease, and the rate of
control of this disease by antihypertensive medications is
very low. Possible ways to lower the prevalence of hyper-
tension in this population include modifying risk factors
such as high weight, eating habits and lack of physical
activity, conducting a polypill intervention program for
primary prevention, and improvement of secondary pre-
vention by increasing hypertension awareness and access
to health services, especially in urban areas and among less
privileged residents.
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530.Reviewer’s Summary Evaluation
Reviewer 1
The strength of the study lies in the large number of study
participants, mainly from a rural area as well as a very
detailed recording of a great number of associated cardio-
vascular risk factors and associated parameters. The
results are representative of the area studied and to
some extent to the Iranian population as well. The studycontributes to our knowledge about the global aspect of
the prevalence, awareness and treatment of hyperten-
sion.
The weakness of the study could be that the prevalence
of hypertension might be somewhat overestimated as only
one blood pressure measurement was done and often
subsequent blood pressure measurement could be some-
what lower. The authors drew attention to this as a limita-
tion of the study.orized reproduction of this article is prohibited.
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